AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$KNTK

ISQ Global Fund II GP LLC (Wahba Sadek, Bhandari Gautam) sold $11.7M of KNTK (indirect holdings)

ISQ Global Fund II GP LLC sold 216,019 indirectly-held shares of Kinetik Holdings Inc. (KNTK) at an average of $54.25 ($53.93–$54.64, $11.72M total) across 4 trades over 2026-10-08 to 2026-10-12. Filed jointly with I Squared Capital, LLC (10% owner), ISQ Holdings, LLC (10% owner), Wahba Sadek (10% owner) and Bhandari Gautam (10% owner).

Original reporting
SEC EDGAR · ISQ Global Fund II GP LLC, I Squared Capital, LLC, ISQ Holdings, LLC, Wahba Sadek, Bhandari Gautam
Published Oct 13, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KNTK
Bearish
high confidence
Mentioned
$KNTK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNTKBearishMed
01

Why it matters

The disclosed sale reduces a major insider's stake dramatically, which may prompt short sellers and cause a price dip.

02

Market read

Primary relevance to KNTK shareholders; minimal broader market effect.

03

What to watch

Potential upcoming clinical data or financing events not disclosed may be driving the sale.

Relevance 6/10Novelty 7/10Timing: after-hours today

Background

Kinetik Holdings Inc. (KNTK) is a micro‑cap biotech listed on NASDAQ. Insider transactions are closely watched for signals.

Company-level read

Ticker impact

$KNTKBearishHigh confidence
Context

Form 4 shows ISQ Global Fund II GP LLC sold ~216k shares of KNTK for $11.7M, reducing its indirect stake to 1 share.

Expected impact

downward pressure as market prices in the insider sale

Evidence & confidence

The sale size ($11.7M) is material for a micro‑cap and the insider is a 10% owner, suggesting potential concerns.

Market effects

Sector

Limited to the biotech/health‑tech niche; no broad sector impact.

Regional

U.S. market focus; no regional ripple.

Global

Low; only relevant to KNTK investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a red flag.

Key entities

  • company
    Kinetik Holdings Inc.

    Issuer of the shares sold.

  • entity
    ISQ Global Fund II GP LLC

    Insider reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KNTK insider trading history →

Related articles

SEP 9
$KNTKMedAI 8/10

Why is Kinetik Holdings stock surging today?

Kinetik Holdings' stock rose 5.2% in after-hours trading after Bloomberg reported the company is exploring strategic alternatives, including a potential sale. The company posted record Q2 2026 results with revenue up 36% YoY and net income more than doubled. Kinetik's management had raised its full-year 2026 guidance. U.S. equities broadly sold off during regular trading hours, with the S&P 500, Dow Jones, and Nasdaq all declining.

investing.com2 min
SEP 9
Med

Kinetik stock jumps 5% on potential sale exploration report

Kinetik Holdings Inc. (KNT) shares rose 5% in after-hours trading after reports it is exploring strategic options, including a potential sale. The company, backed by Blackstone Inc. (BX), has a market value of $8.9B. No final decision has been made. Kinetik closed regular trading at $54.55, down 0.8% but up 30% over the past year.

investing.com2 min